Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with ...

Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response ...

Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation ...

CAR T-cell therapy genetically alters a patient's immune cells to fight certain cancers like lymphoma and leukemia.

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

CAR-T therapy, previously used for treating blood cancers, has opened a new path for patients who struggled to receive kidney ...

A dual-target CD19/BCMA chimeric antigen receptor T-cell therapy yielded “profound, sustained” remission in 11 patients with ...

Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

CAR T-cell therapy successfully cleared anti-HLA antibodies to enable kidney transplantation in three highly sensitized patients. Treatment was well-tolerated and no donor-specific antibody rebound ...